

For Immediate Release

Singapore Institute of Advanced Medicine Holdings enters into a strategic partnership with Australia-based biopharmaceutical company, EnGeneIC to revolutionize cancer treatment in Asia

- Dual-pronged expansion of revenue streams through profit-sharing agreement
 - SAM Holdings will have exclusive distribution rights for sales of EDV therapeutics in 17 countries within Asia.
 - Both parties will also collaborate on the development of EDV-based Theranostics to improve cancer outcomes and SAM Holdings will be granted exclusive distribution rights worldwide.
- Investing into next generation technology to achieve our core vision
 - First-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads via antibody-targeting a cancer cell's surface, with minimal toxicity.
 - EDV-based theranostics can provide precise, personalized care, enabling early detection and targeted therapy, which aligns with the Group's vision.
- The partnership will bring the latest cancer treatment innovation to Singapore and increase Singapore's attractiveness as the medical tourism hub of Asia.

Singapore, 10 June 2024 – Singapore Institute of Advanced Medicine Holdings Ltd. (“**SAM Holdings**” or the “**Company**”, and together with its subsidiaries, the “**Group**”), has entered into a strategic partnership with EnGeneIC Pty Limited (“**EnGeneIC**”), an Australia-based clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy. The partnership aims to revolutionize the cancer treatment landscape in Asia and provide better outcomes of life for our patients.

Under the partnership, the Group will collaborate with EnGeneIC on a profit-sharing basis for:

- Manufacturing and distribution of anti-cancer products based on EnGeneIC's proprietary technology platform, EnGeneIC Dream Vector (“**EDV-based Products**”); and
- Development of EnGeneIC Dream Vector-based theranostics for use in the imaging and treatment of various cancers (“**EDV-based Theranostics**”).

EDV-based Products

The Group will help EnGeneIC secure funding and regulatory authorizations for building a manufacturing plant in Singapore for the manufacture of EDV-based Products, conduct clinical

trials in Singapore, and obtain regulatory authorization to market and sell the EDV-based Products. In turn, SAM Holdings will be granted exclusive distribution and marketing rights of these products in 17 countries within Asia.

EDV-based Theranostics

Leveraging on the Group's experience in theranostics, it will collaborate with EnGeneIC for pre-clinical testing of EDV-based Theranostics and obtain regulatory approval for commercialization and sale of EDV-based Theranostics. Subsequently, the Group will be granted exclusive distribution rights worldwide for EDV-based Theranostics.

Commenting on the partnership, Dr Djeng Shih Kien, Executive Director and CEO, and founder, of SAM Holdings, said, "We have always been committed to providing our patients with easier access to the latest cancer treatment technologies and our partnership with EnGeneIC is another step forward in that direction. We are excited at the prospect of bringing cutting edge EDV-based therapeutics to Singapore and Asia and collaborating on the development of EDV-based Theranostics. Our experience in cancer treatment coupled with EnGeneIC's advanced medical innovations will propel us forward in our journey to provide early diagnosis and better outcomes for our patients throughout the region."

- - End - -

*Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

About Singapore Institute of Advanced Medicine Holdings Ltd. (“SAM Holdings”)

Incorporated in 2011, SAM Holdings is a healthcare service provider using advanced technology for early and accurate diagnosis and offering appropriate treatments to achieve better outcomes and quality of life for our patients. The Group’s services cater to a wide spectrum of diseases and health conditions including, but not limited to, cancer, neurodegenerative and cardiovascular disease detection, and treatment. The Group is primarily engaged in two key business segments: (i) Medical Diagnostics and Treatments; and (ii) Radiation Therapy and Medical Oncology Services.

The goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer. The Group aims to do this by bringing together a dedicated team of professionals and experts from the industry who will empower them to take away the fear of cancer by finding the answers and solutions for the diagnosis, treatment, and ongoing quality of life improvements for cancer patients. For more information, please visit SAM Holdings’ website at www.advancedmedicine.sg.

About EnGeneIC

EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV[®] (EnGeneIC Dream Vector) nanocell technology for oncology and infectious disease applications. The EDV[™] nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads -- drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell’s surface, with minimal toxicity. For cancer applications, the EDV technology enables delivery of the most potent chemotherapeutic agents, effectively overcoming drug-resistance and killing tumor cells, while simultaneously stimulating the patient’s immune system, allowing a potent ant-tumour response. EnGeneIC is now entering Phase IIa clinical trials in Australia and USA in patients with intractable, low survival cancers, including patients with metastatic pancreatic cancer.

Issued for and on behalf of Singapore Institute of Advanced Medicine Holdings Ltd.

By Financial PR Pte Ltd

For more information please contact:

Shivam SARAF / Kamal SAMUEL

Financial PR Pte Ltd

Tel: 6438 2990 / Fax: 6438 0064

E-mail: shivam@financialpr.com.sg / kamal@financialpr.com.sg